A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses.

Publication date: Jul 22, 2024

The development of broad-spectrum coronavirus vaccines is essential to prepare for future respiratory virus pandemics. We demonstrated broad neutralization by a trivalent subunit vaccine, formulating the receptor-binding domains of SARS-CoV, MERS-CoV, and SARS-CoV-2 XBB. 1.5 with Alum and CpG55. 2. Vaccinated mice produced cross-neutralizing antibodies against all three human Betacoronaviruses and others currently exclusive to bats, indicating the epitope preservation of the individual antigens during co-formulation and the potential for epitope broadening.

Open Access PDF

Concepts	Keywords
Bats	Antibodies
Betacoronaviruses	Based
Cpg55	Betacoronavirus
Essential	Broad
Vaccinated	Coronavirus
	Cov
	Cross
	Epitope
	Neutralizing
	Pan
	Protein
	Sars
	Trivalent
	Vaccine
	Vaccines

Semantics

Type	Source	Name
disease	VO	vaccine
disease	VO	subunit vaccine
disease	VO	vaccinated
disease	MESH	severe acute respiratory syndrome
disease	MESH	Middle East respiratory syndrome
disease	VO	coronavirus vaccine
disease	MESH	COVID 19 pandemic
disease	VO	Corbevax
disease	VO	dose
disease	MESH	emergency
disease	VO	prime boost regimen
disease	VO	USA
disease	VO	vaccination
disease	VO	immunized
drug	DRUGBANK	Coenzyme M
disease	VO	effective
drug	DRUGBANK	Tromethamine
disease	VO	injection
disease	VO	vaccine dose
drug	DRUGBANK	Aluminum hydroxide
drug	DRUGBANK	Aspartame
disease	VO	intramuscular route
drug	DRUGBANK	Ketamine
drug	DRUGBANK	Xylazine
disease	IDO	blood
disease	VO	protocol
disease	IDO	humoral immune response
drug	DRUGBANK	Puromycin
drug	DRUGBANK	Dextrose unspecified form
drug	DRUGBANK	L-Glutamine
drug	DRUGBANK	Benzylpenicillin
drug	DRUGBANK	Streptomycin
disease	IDO	cell
disease	MESH	infection
disease	VO	Primates
disease	VO	immunization
drug	DRUGBANK	Huperzine B
drug	DRUGBANK	(S)-Des-Me-Ampa
disease	IDO	production

Original Article

(Visited 2 times, 1 visits today)